Disclosed is the use of a peptide of the following sequence: Phe-Thr-Asp-Asn-Tyr-X wherein X is absent or selected from the group consisting of: -Thr-Arg； -Thr-Arg-Leu-Arg-Lys-Gln； -Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys； and -Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn or conservative substitutions thereof, for the manufacture of a medicament for the prophylactic or therapeutic treatment of chronic kidney disease in a subject, wherein the chronic kidney disease is associated with kidney fibrosis.
